Big Update on Indian Vaccine against COVID-19
A lot of countries are in the race of finding vaccine as a prevention to the deadly virus of COVID-19.
Russia has already unveiled its vaccine ‘Sputnik V' in the market and has started its manufacturing. But, on the other hand it has also landed up in a lot of debates as it has not completed the round of final trial due to which a major part of specialists is showing disagreement over its usage.
News of side effects have also poured in the mainstream media.
In the same race, India's candidate COVAXIN is quite ahead too.
As per reports, the first human clinical trial has successfully completed and has showed very promising results.
It has indicated safe signs.
Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) have developed this vaccine of COVAXIN for coronavirus.
The second round of trials is expected to start in first week of September.
All the trials are being conducted and regulated at AIIMS, New Delhi.
PHASE 1 : Status
Total no. of volunteers: 375
End date: by last week of August
Region: at different sites across India including New Delhi and other metro cities.